The explanation of long-run growth in the value of per capita output is a central issue in economics. In recent years, economists have increasingly recognized that traditional, official measures of growth in real per capita output significantly understate true economic growth. One reason is that the price indices that are used to deflate nominal output tend to overestimate inflation, by approximately 1-1.5 percentage points per year (CPI Commission Report).
A second reason is that GDP does not fully account for several important, highly-valued "commodities," such as leisure, health, and longevity. The average person born in 1995 expects to live 22 years (41%) longer than the average person born in 1920. Although the rate of increase of longevity appears to be declining, as Table 1 indicates, between 1970 and 1991 mean age at death still increased 5.4 years. In a recent paper, Nordhaus (1998) argues that the underestimation of economic growth resulting from failure to account for increased longevity is substantial: he estimates that, "to a first approximation, the economic value of increases in longevity over the twentieth century is about as large as the value of measured growth in non-health goods and services" (p. 17). In other words, economic growth adjusted for longevity increase is twice as large as unadjusted economic growth.
The Solow model, which is perhaps the most widely-accepted theory of economic growth, implies that technological progress is the fundamental source of growth in per capita income.
While early models of growth treated the rate of technological progress as an exogenous variable, more recent ("endogenous growth") models recognize that technological progress depends on investment in research and development (R&D) and on the creation of new products and processes.
There is abundant empirical evidence that supports the hypothesis that the growth in conventionally-defined per capita output (or total-factor productivity) is positively related to previous investments in research and development. Griliches and Lichtenberg (1984) , for example, found that the most R&D intensive manufacturing industries tend to have the highest rates of growth of output per worker.
In this paper, we investigate econometrically whether the "other" (unmeasured) half of economic growth-the increase in longevity-can also be explained by a certain kind of technological progress: the development and diffusion of new drugs. Since Nordhaus argues that increased longevity accounts for half of total U.S. economic progress, and Bresnahan and Gordon claim that, in general, "new goods are at the heart of economic progress," the hypothesis that new drugs deserve a substantial amount of credit for increased longevity seems quite plausible.
Econometric investigations of the impact of technological change are usually hampered by lack of reliable data. In the case of pharmaceuticals, however, it is possible to identify, date, and classify every major and minor innovation since 1939 (because the industry has been strictly regulated by the FDA since then), and to measure the consumption (utilization) of about 900 distinct drugs (molecules) since 1980. We obtained from the Food and Drug Administration (by submitting a Freedom of Information Act request) a computerized list of all New Drug Approvals (NDAs) and Abbreviated New Drug Approvals (ANDAs) since 1939. The list includes the NDA or ANDA number, the approval date, the generic and trade names of the drug, the dosage form, route of administration, strength, applicant name, "therapeutic potential" (priority or standard), and "chemical type" (new molecular entity, new formulation, new manufacturer, etc.). This enables us to reconstruct the precise history of pharmaceutical innovation during the last almost 60 years.
We obtain data on the utilization (market shares) of various drugs from the 1980 and 1991 National Ambulatory Medical Care Surveys (NAMCS), which survey doctor-office visits, and the 1993 National Hospital Ambulatory Medical Care Survey (NHAMCS), which surveys visits to hospital outpatient departments and emergency departments.
1 These surveys enable us to estimate the number of drug "mentions" (prescriptions), by molecule, in 1980 and subsequent years.
Time-series data on the number of new molecular entities (NMEs) approved by the FDA are shown in Table 2 . More than half of the 1352 NMEs that the FDA has approved since its inception were approved after 1980. It is therefore not surprising that, as Table 3 shows, the We analyze the relationship across diseases between the long-term reduction in life-years lost before age 75 and the relative utilization of new pharmaceutical products. In other words, we investigate whether there were above-average reductions in mortality from diseases for which there were above-average utilization rates of new drugs. By combining the FDA and NAMCS data, we can calculate (subject to some measurement problems) disease-specific measures of 1 The National Center for Health Statistics first administered the NHAMCS in 1992. Unfortunately, there are no publicly-available data on pharmaceutical utilization in an inpatient setting.
pharmaceutical innovation, i.e. quantify the amount of innovation relevant to each disease, since NAMCS reveals the relative frequency with which each drug is used for each disease.
This methodology controls for the effects of any general economic and social trends (such as changes in wealth, nutrition, or sanitation) that affect average mortality. The analysis of mortality change in a cross section of diseases seems quite analogous to the analysis of output or productivity growth in a cross section of industries. Industries produce goods; diseases may be considered "bads," or negative goods. The extent of innovation varies across both industries and diseases, due, in part, to variation in the extent of "technological opportunity."
We estimate this relationship for the entire period 1970-91 and for two sub-periods (1970-80 and 1980-91) , and for different categories of disease (based on the average age at which people die from the disease). We also distinguish between "drugs that appear (to the Food and Drug Administration) to represent an advance over available therapy," ("priority drugs") and "drugs that appear to have therapeutic qualities similar to those of already marketed drugs" ("standard drugs"
). The data we analyze cover all diseases and all (outpatient) drugs, thus allowing us (assuming that our model is correctly specified) to draw general conclusions about the impact of new drugs on longevity, which it is not possible to do from existing studies, which are about specific diseases and/or drugs.
In the next section we briefly review some of the previous evidence on the impact of drugs on life expectancy, including anecdotal evidence, a case study of a specific disease (heart attacks), and data from a few clinical studies of specific drugs. In section III we present a simple econometric model for estimating this impact, describe our procedures for constructing the variables included in this model, and discuss issues pertaining to estimation and interpretation of parameter estimates. Estimates of the model and their economic implications are discussed in Section IV. The effects of controlling for physician counseling, vaccine availability, and surgical innovation are presented in Section V. An estimate of the social rate of return to pharmaceutical innovation is derived in Section VI. The final section contains a summary and conclusions.
II. Previous evidence
PhRMA (1998) provides an informal, anecdotal account of the contribution of drug innovation to medical progress in this century. We simply quote their account here:
Antibiotics and vaccines played a major role in the near eradication of major diseases of the 1920s, including syphilis, diphtheria, whooping cough, measles, and polio.
Since 1920, the combined death rate from influenza and pneumonia has been reduced by 85 percent. Despite a recent resurgence of tuberculosis (TB) among the homeless and immuno-suppressed populations, antibiotics have reduced the number of TB deaths to one tenth the levels experienced in the 1960s. Before antibiotics, the typical TB patient was forced to spend three to four years in a sanitarium and faced a 30 to 50 percent chance of death. Today most patients can recover in 6 to 12 months given the full and proper course of antibiotics.
Pharmaceutical discoveries since the 1950s have revolutionized therapy for chronic as well as acute conditions. From 1965 to 1995 cardiovascular drugs such as antihypertensives, diuretics, beta blockers, and ACE inhibitors drastically reduced deaths from hypertension, hypertensive heart disease, and ischemic heart disease. Similarly, H2 blockers, proton pump inhibitors and combination therapies cut deaths from ulcers by more than 60 percent. Anti-inflammatory therapies and bronchodilators reduced deaths from emphysema by 31 percent and provided relief for those with asthma. Had no progress been made against disease between 1960 and 1990, roughly 335,000 more people would have died in 1990 alone.
Since 1960, vaccines have greatly reduced the incidence of childhood diseasesmany of which once killed or disabled thousands of American children. Likewise, vaccines for Hepatitis B introduced during the 1980s now protect a new generation of American children from a leading cause of liver disease.
Brand new evidence indicates that new drug therapies have sharply reduced fatalities from AIDS: AIDS deaths in New York City plummeted by 48 percent last year, accelerating earlier gains attributed to improved drug therapies…the declines crossed sex and racial lines, suggesting that the new therapies were reaching all segments of the AIDS population. National figures for the first six months of 1997 also showed a similar sharp decline, 44 percent, from the corresponding period of 1996…Theoretically, the decline in AIDS deaths could have resulted from prevention efforts or some unknown factor…But the likeliest explanation is expanded use of combinations of newer and older drugs that began to be introduced in recent years, New York City and Federal health officials said.
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The anecdotal evidence about the impact of new drugs on mortality is in stark contrast to econometric evidence presented by Skinner and Wennberg (1998) about the relationship between total medical expenditure in the last six months of life and outcomes.
4 They analyzed this relationship using both a 20% sample of all Medicare enrollees and a 5% sample of very ill
Medicare patients hospitalized with heart attack (AMI), stroke, gastrointestinal bleeding, and lung cancer. Per capita medical expenditures vary considerably across regions. For example, average
Medicare expenditures on elderly patients in the last six months of life are twice as high in Miami 2 Dustan et al (1996) arrive at a similar conclusion: "In the past 2 decades, deaths from stroke have decreased by 59% and deaths from heart attack by 53%. An important component of this dramatic change has been the increased use of antihypertensive drugs." 3 "AIDS Deaths Drop 48% in New York," New York Times, February 3, 1998, p. A1. 4 Pharmaceutical expenditure accounts for about 10% of total U.S. health expenditure.
as they are in Minneapolis, and the average number of visits to specialists is five times as high.
However intensive econometric analysis provided "no evidence that higher levels of spending translates into extended survival." pravastatin reduces the risk of heart attack and death in a broad range of people, not just those with established heart disease, but also among those who are at risk for their first heart attack…Over five years, those [healthy individuals] treated with…pravastatin suffered 31 percent fewer nonfatal heart attacks and at least 28 percent fewer deaths from heart disease than a comparable group of men who received a placebo…In previous studies, pravastatin had been shown to reduce the risk of heart attack by 62 percent in patients with high cholesterol who already had heart disease.
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Evidence from clinical trials is extremely useful and of great scientific value, but some public health experts argue that clinical-trial results cannot simply be extrapolated to real-world experience. Also, there does not appear to be any way to summarize or combine all of the clinicaltrial evidence to shed light on the average or aggregate contribution of pharmaceutical innovation to mortality reduction and economic growth, which is our goal.
III. Model specification and estimation
To assess the contribution of pharmaceutical innovation to the reduction in ("premature") mortality of Americans, I will perform several different analyses of the relationship, across diseases, between the relative utilization of new drugs and the reduction in life-years lost, including estimation of models of the form The independent variable in eq. (1) is the fraction of drugs prescribed in 1991 that were approved in 1970 or later. We hypothesize that the greater the percentage of drugs prescribed in 1991 that were not yet available in the "baseline" year (1970), the greater the reduction in mortality since the baseline year. 12 We recognize that, due to a heterogeneous rate of obsolescence of drugs across diseases, a given value of the new drug share may reflect varying degrees of drug improvement. Suppose that for disease A, there is only one drug approved after 1970, and this has a 50% market share in 1991. For disease B, one new drug is approved in 1975, and it captures 50% of the market; another drug is approved in 1985, and all patients on the first drug (and only those patients) switch to the second drug. Disease B has the same new drug share in 1991 as disease A, even though it has benefited from two waves of innovation, rather than one. Although diseases with a given new drug share may have different rates of drug improvement, we postulate that, on average, diseases with higher new drug shares have higher rates of drug improvement.
This specification is very consistent with the most widely-accepted theory of economic growth, i.e. the Solow model. As Mankiw (1992, p. 102) observes, the Solow model implies that "once the economy is in a steady state, the rate of growth of output per worker depends only on the rate of technological progress." We argued above that mortality reduction may be interpreted as a component or form of per capita income (or output) growth. As Bresnahan and Gordon (1997, p. 1) observe, "new goods are at the heart of economic progress," so the fraction of all goods (drugs)
consumed that are new appears to be a very appropriate measure of the rate of technological progress.
Although there is only one variable on the right-hand side of eq. (1), the validity of our analysis is not based on the assumption that pharmaceutical innovation is the only source of mortality reduction. Changes in mortality are likely to depend upon a number of factors, such as changes in wealth, changes in environmental quality, and changes in the prevalence of smoking. If the changes in these other factors were "across the board" changes-they did not vary across diseases-then their effect would be captured by the intercept term ( α), which reflects the mean reduction in mortality not explained by pharmaceutical innovation (α = mean(Y) -β mean (X)).
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Our estimates of, and hypothesis tests about, the effect of pharmaceutical innovation on mortality reduction (β) depend entirely on diseases' deviations from sample means and not at all on the mean values of Y and X.
It is likely, of course, that changes in these other factors vary to some extent across diseases. If determinants of mortality change other than pharmaceutical innovation are uncorrelated across diseases with pharmaceutical innovation, then eq. (1) still yields unbiased estimates of β. 14 There does not appear to be good reason to expect changes in most determinants of mortality other than drug innovation to be correlated across diseases with drug innovation. It is not obvious, for example, why diseases for which many new drugs were developed should be the ones whose sufferers reduced smoking the most or whose wealth increased the most. 15 Ideally, one might estimate an expanded version of eq. (1) that includes a large number of other potential determinants of mortality change. Many of these are difficult or impossible to measure at the disease level. But there are several potentially relevant covariates that we can measure, and will include in more elaborate model of mortality reduction (presented in Section V), to check the robustness of our estimates. These are: (1) the probability that the physician provides nonmedication therapy-primarily counseling and education-to the patient; (2) a dummy variable indicating whether or not a vaccine is available for a disease; and (3) the rate of introduction of new surgical procedures
The ICD9 classification includes three kinds of codes: disease (or natural causes of death) codes (000-799), nature of injury codes (800-999), and external causes of death codes (E800-E999). 16 In the mortality files, only the first and last sets of codes are used, whereas in the ambulatory care surveys, only the first and second sets of codes are used. We therefore confine our analysis to diseases (natural causes of death).
Eq.
(1) can be estimated using data at different levels of aggregation. It could be estimated, for example, using either ICD9 2-digit or 3-digit level disease data (at which there are 80 and ---diseases, respectively). There is no theoretical reason to believe that the parameter estimates should depend in any particular way on the level of aggregation. As a practical matter, greater disaggregation has both advantages and disadvantages. 17 The advantages are that the number of observations (and statistical degrees of freedom) increases, and that each observation is less heterogeneous (covers a less diverse group of diseases). The disadvantages are that both measurement or classification error (in the dependent variable) and sampling error (in the independent variable) are amplified. Murray and Lopez (1996, p. 16) note that "miscoding of deaths-that is, assigning the death to the "wrong" cause in ICD-9, occurs regularly in all countries with registration systems. For example, the choice of codes for cardiovascular diseases is notoriously variable between industrialized countries, with a significant proportion of ischaemic heart disease deaths being attributed to ill-defined codes such as heart failure." Since we are analyzing changes in mortality, by disease, our estimates would not be affected by systematic (permanent) miscoding of deaths, e.g. if ischaemic heart disease deaths were always underestimated by 25%. But the miscoding of cause of death is likely to have a random component as well, and the probability that a 3-digit diagnosis is wrong is undoubtedly much greater than the probability that a 2-digit diagnosis is wrong. The greater the extent of miscoding, the lower the precision of our parameter estimates. As we will describe below, the data we use on the new-drug share are estimates based on random 1 in 10,000 or 1 in 16,000 samples of doctor office visits.
The greater the extent of disaggregation by disease, the smaller the number of visits in each disease category, and the larger the sampling error associated with each observation. Amplification of sampling error biases the coefficient on the new-drug share towards zero, i.e. it increases the probability of finding no relationship between pharmaceutical innovation and mortality reduction 15 The extent of drug innovation seems more likely to depend on the level of average wealth than on its growth rate. 16 There is no direct correspondence between the nature of injury codes and the external cause of death codes, e.g. 821 does not correspond to E821.
when there really is a relationship. Since the statistically optimal level of disease aggregation is not obvious a priori, we tried performing the analysis at both the 2-digit and the 3-digit level. The 2-digit-level estimates were more significant and robust, so these are the ones that we will present.
Estimates of DRUGS t-k,t -the number of drugs prescribed in year t that received FDA approval in year t-k or later-were obtained by combining data from several sources. could be coded in a single record. The record also lists up to three diagnoses (ICD9 codes), and a "drug weight", which is used to compute population-level estimates of drug utilization from the sample data. Because multiple diagnoses may be cited in a given record, we sometimes confront the problem of "allocating" the mention of a drug across diagnoses. We adopted the simple, feasible, approach of equal allocation of the drug mention across the several diagnoses. For example, if two diagnoses were cited and the drug weight was 10,000, we replaced the mention of that drug by two mentions of the same drug, one for each diagnosis, each with a drug weight of 5000; this procedure does not change the population estimates of drug mentions, by molecule. We then calculated estimates of the aggregate number of prescriptions, by molecule and patient diagnosis.
To calculate the fraction of drugs that were approved by the FDA after a certain date, we linked these data to a list of all New Drug Applications since 1939 provided by the FDA. Both files included the scientific name of the drug, and the FDA file included the date the drug was first approved as a new molecular entity (NME).
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17 For a discussion of the statistical tradeoffs associated with aggregation, see Griliches (19__) . 18 The FDA data enable us to identify the dates of "minor" innovations-new formulations of existing molecules-as well as the dates of "major" innovations-new molecules. In the course of the approval process, the FDA classifies drugs into two categories:
"priority review drugs"--drugs that appear to represent an advance over available therapy--and Table 4 shows the percentage distribution of drugs prescribed in 1980 that were less than 10 years old, by drug class. The top three classes of new drugs were drugs used for relief of pain, antimicrobial agents, and respiratory tract drugs; together these accounted for about half of new drug prescriptions. The lower panel of Table 4 shows the percentage distribution of drugs prescribed in 1991 that were less than 11 years old, by drug class.
Cardiovascular-renal drugs accounted for over a third of the new drugs prescribed in 1991, more than four times their share of new drugs in 1980; the new-drug share of hormones also increased sharply. As Table 5 indicates, the average age of patients receiving drugs varies significantly across drug classes. The average age of patients receiving drugs used for relief of pain-the largest new drug class in 1980-is 48, while the average age of patients receiving cardiovascular-21 The FDA' s stated goal is to review and act on complete applications for "priority" drugs within six months of an NDA's submission date, and to review and act on NDAs for "standard" drugs within 12 months. However until the recent prescription drug fee legislation, few drugs were approved within 6 months. All AIDS drugs are classified as priority drugs. 22 Of course, new drugs may confer health and economic benefits to patients other than mortality reduction. In future research, we plan to investigate the effect of pharmaceutical innovation on morbidity and "quality of life" using data from National Health Interview Surveys. (If, as we argue in this paper, new drugs tend to reduce mortality, one should examine the impact of pharmaceutical innovation on morbidity reduction controlling for mortality reduction, since new drugs are likely to keep less healthy people alive.) The introduction of a new, standard drug is likely to make the market for drugs in that class more competitive, and to lower prices to consumers. 23 Many economic relationships are stronger in the long run than they are in the short run. For example, as observe, the relationship between consumption expenditure and disposable income is stronger in the long run than it is in the short run.
renal drugs-the largest new drug class in 1991-is 66. Further calculations show that, consistent with this, the average age of patients receiving any new drug in 1980 was 44, whereas the average age of patients receiving any new drug in 1991 was 52. Since the clientele for drugs introduced in the 1980s tended to be older than the clientele for drugs introduced in the 1970s, one would expect the mortality reductions in the 1980s to be more concentrated among older patients. We will test this prediction by estimating eq (1), for different categories of diseases, classified by the mean age at which people die from the disease.
The dependent variable in eq. (1) is the log-change (growth rate) of per capita life-years lost, ln (LYL t-k / LYL t ). The variance of the dependent variable is strongly inversely related to the average size or burden of the disease, (LYL t-k + LYL t ) / 2. The growth rates of diseases affecting a relatively small number of people are likely to be much farther away (in both directions) from the mean than those of major diseases. 24 To correct for heteroskedasticity, the equation is estimated via weighted least squares, where the weight is (LYL t-k + LYL t ) / 2. Diseases that are responsible for larger average numbers of life-years lost are given more weight.
There are a number of reasons why estimates of the parameters of eq. (1) might be biased.
Several considerations imply that estimates of β will be biased towards zero, and therefore that our hypothesis tests will be strong tests. Measurement error in the new-drug proportion is perhaps the main reason to suspect downward bias. 25 The variable we calculate (DRUGS t-k,t / DRUGS .t ) may be a noisy measure of the true share of new drugs for a number of reasons: (1) Sampling error: the NAMCS survey is a random 1 in 10,000 or 1 in 16,000 sample of doctor office visits; (2) Coverage: our drug data refer only to doctor-office visits in 1980, and to outpatient visits in 1991 24 To illustrate this, we estimated the unweighted regression of the log change between 1980 and 1991 in LYL on the share of new, priority drugs in 1991, and computed the absolute value of the residuals from this regression. We then divided the diseases into three size categories, based on the average number of LYL in 1980 and 1991. The means of the absolute residuals in each of the three size groups were: smallest 0.322 middle 0.288 largest 0.137. Also, there is a highly significant (p-value < .01) inverse correlation between the absolute residual and the logarithm of mean LYL. 25 The consequences of random measurement error in the independent variable are well known to econometricians. Suppose the true model is y = β x* + u, but x* is not observed; instead we observe x = x* + e, where e is a random error term, with mean zero and variance σ e 2 . Then E(b) = β (σ * 2 / (σ * 2 + σ e 2 )) where b is the OLS slope coefficient, and σ * 2 is the variance of x*. The larger the "noise-to-signal ratio" ( σ e 2 / σ * 2 ), the greater the bias towards zero of b.
(no inpatient data), and primarily refer to prescription, rather than over-the-counter, drugs 26 ;
Misallocation of drugs to diseases resulting from errors in allocation procedure described above (when there are multiple diagnoses); (4) Noncompliance: Our data refer to drugs prescribed by physicians, not drugs consumed by patients. It is estimated that only about half the medicine prescribed is taken correctly. The National Council on Patient Information & Education divides the problem of noncompliance into two categories: acts of omission and acts of commission. Acts of omission include: never filling a prescription; taking less than the prescribed dosage; taking it less frequently than prescribed; taking medicine "holidays"; stopping the regime too soon. Acts of commission include: overuse, sharing medicines, consuming food, drink or other medicines that can interact with the prescribed drug.
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It is plausible that reverse causality (endogenous innovation), as well as measurement error in the independent variable, could bias estimates of β towards zero. Suppose that there is a significant anticipated increase in fatalities from a certain disease (such as AIDS), and that this prospect stimulates a high rate of development and diffusion of new drugs targeted at that disease.
Behavior of this sort would reduce the probability of observing a positive relationship across diseases between mortality reduction and new drug utilization.
We can also think of one possible reason for the least-squares estimate of β to be biased upwards, i.e. to overestimate the average contribution of pharmaceutical innovation to medical progress. Suppose that the rate of progress (P) against a disease is a deterministic, concave function of research expenditure on the disease (X) and research productivity ( π ): P i = π i X i θ , where i denotes disease i and 0 < θ < 1. Taking logarithms of the progress function, ln P i = ln π i + θ ln X i . Suppose that disease-specific research productivity (π i ) is unobservable. If π i were uncorrelated with research expenditure X i , the least-squares estimate of the elasticity of progress with respect to spending θ would be unbiased. However, as argued in Lichtenberg (1997) , if decision-makers are efficiently allocating the research budget across diseases (i.e. to maximize the total number of people cured of all diseases), they should devote more research funds to diseases where research productivity is high. Therefore π i and X i are likely to be positively correlated, and the slope coefficient from the simple regression of ln P i on ln X i would overestimate θ. More progress tends to be made on diseases with high research funding in part because those are the diseases where research productivity is highest. We are examining the relationship between progress and the new drug proportion, not research expenditure, but the latter two variables are likely to be positively correlated.
IV. Empirical results
Descriptive statistics for the dependent and independent variables for 2-digit ICD9 diseases over the 1970-91 period and the two sub-periods are shown below. The weighted-average decline in per capita LYL during the period 1970-91 was 42.9% ( = 1 -exp (-.561)); 5% of diseases exhibited a decline of more than 85%; however 5% of diseases exhibited an increase of at least 117.3%.
As the following table indicates, the mean shares of drugs prescribed in 1991 that were approved after 1970 and 1980, computed from NAMCS data, are quite close to the shares of drugs approved by the beginning of 1991 that were approved after 1970 and 1980, computed from FDA data.
Period % of drugs prescribed at the end of the period that were % of drugs approved by the end of the period that were 28 We attempted to explore the relationship across drug classes between unpublished PHARMA data on R&D intensity (the ratio of R&D expenditure to sales) and our data on the share of new drugs in total prescriptions. Unfortunately, the PHARMA data are available for only eight highly aggregated drug classes (e.g. cardiovascular drugs), and we failed to find a statistically significant relationship based on such a small sample. 31 In contrast, all of the top five drugs prescribed to patients diagnosed with pneumonia and influenza were new drugs, and the decline in per capita life-years lost (74%) was well above average. The data for these two diseases are consistent with the hypothesis that utilization of new drugs reduces mortality, but we need to analyze data on the full cross-section of diseases in order to have meaningful, general tests of this hypothesis.
Key econometric results are summarized in Table 7 . The first part of the table reports estimates of our basic model (eq. (1)), by period. The second part reports estimates of models in which we allow priority and standard drugs to have different effects on mortality. The third part 29 If the coefficient from the regression of Y on X is b, the coefficient from the regression of Y on (X / 2) is 2b. The t-statistic on b and the R 2 of the two regressions are the same. 30 Since, as noted above, patients may have multiple diagnoses, the drugs are not necessarily prescribed for these diseases. 31 Fortunately, however, at the present time many people expect that there will soon be a number of highly effective drugs to fight cancer.
reports the results of estimating the basic model separately for three different groups of diseases, classified by the mean age at which people die from the disease.
Part I of the table indicates that there is a highly significant positive relationship between the new drug share and mortality reduction in all three periods. The magnitude and significance of the effect of the new drug share on mortality reduction is much higher in 1970-80 than it is in 1980-91. As noted above, the ratio of the 1970-80 point estimate of β to the 1980-91 estimate may be overstated by a factor of about 2 due to apparent systematic underestimation of the new drug share in the first period. But even in the second period, we can reject the null hypothesis of no relationship between these two variables at about the 2 percent level. The magnitude and significance of β is larger over the entire 21-year period than it is in either of the two sub-periods. This is consistent with the view that the long-run effects of new drugs on mortality are larger than the short-run effects. Over 40 percent of the variation across diseases in the 1970-91 reduction in mortality is explained by the new drug share.
We wanted to ensure that our estimates were not unduly affected by a small number of highly influential observations. Following Belsley, Kuh, and Welsch (1980) , we used the studentized residual with the current observation deleted (RSTUDENT) as the measure of that observation' s influence. This statistic is approximately distributed as standard normal 32 , so that if RSTUDENT is greater than two, "the particular observation may deserve scrutiny as perhaps not conforming to the model" (Greene (1997), p. 445) . Estimating the 1970-91 model excluding 7 observations for which the absolute value of RSTUDENT exceeds two 33 reduces β, but not dramatically--by about 25%, from 2.87 to 2.14. The coefficient remains highly significant (t=4.26). Moreover, Greene (1997, p. 411) states that there is a "general principle that allowing the data and the values of sample test statistics to dictate the form of the model can lead to estimators with demonstrably poor statistical properties," and that "there is a certain danger in singling out particular observations for scrutiny or even elimination from the sample on the basis of 32 In our sample, we can' t reject the null hypothesis that the studentized residuals are a random sample from a normal distribution (p-value=.24). 33 The studentized residuals for these observations are: -2.89 (Other forms of heart disease (420-429)), -2.56 (Chronic obstructive pulmonary disease and allied conditions), -2.43 (Malignant neoplasm of respiratory and intrathoracic organs), -2.23 (Nonspecific abnormal findings Ill-defined and unknown causes) , 2.21 (Acute rheumatic fever (390-392) and chronic rheumatic heart disease), 2.60 (congenital anomalies), and 2.83 (Other conditions originating in the perinatal period (764-77)).
statistical results that are based on those data. At the extreme, this may invalidate the usual inference procedures" (p. 415).
An alternative way of analyzing this relationship is to group diseases into a number of categories, on the basis of the new drug share, and to calculate the mean reduction in mortality for each group of diseases. The results from performing this procedure on the 1970-91 data with the number of groups equal to four are summarized in the figure below. The estimates in part II of Table 7 indicate that in the 1970-80 period, only priority drugs had a statistically significant effect on mortality reduction. In the 1980-91 period, the coefficient on priority drugs is larger than the coefficient on standard drugs, but we cannot reject the hypothesis that the effects of the two types of drugs are the same. The same is true for the 1970-91 period as a whole, so the data provide only weak support for the view that new priority drugs reduce mortality more than new standard drugs.
The estimates in part III of the table indicate that in the 1970-80 period, new drugs reduced mortality in the lowest and middle thirds of the age-distribution of diseases-especially in the former-but not in the highest third of the distribution. In contrast, in the 1980-91 period, new drugs had a significant positive effect on mortality reduction only in the highest third of the age distribution. Hence, new drugs appear to have reduced mortality in all three age categories in one of the two periods. In Tables 4 and 5 we showed that the drugs introduced in the 1980s tended to be targeted at older patients than the drugs introduced in the 1970s, so the "vintage-age interaction" evident in Table 7 is not at all surprising.
V. The effects of controlling for physician counseling, vaccine availability, and surgical innovation As discussed earlier, the (simple regression) coefficients on pharmaceutical innovation presented in Table 7 could be biased due to failure to control for other determinants of mortality reduction. Improved patient knowledge about the impact of behavior on health is a potentially important source of mortality reduction. Although this knowledge can be acquired in a number of ways (e.g. via the mass media), counseling by physicians is likely to be a major means of knowledge acquisition. According to 1991 NAMCS data, physicians provide therapeutic services other than medication in about one-third of office visits (they prescribe medications in about twothirds of visits). Most of these non-medication therapeutic services are in the form of counseling and education; the kinds of counseling and education offered are as follows:
Type The probability that non-medication therapeutic services are offered varies according to patient diagnosis. For example, some kind of non-medication therapy is provided to almost half of patients with hypertension, but to only 10% of patients with upper respiratory tract diseases. We will attempt to control for the effect of improved patient knowledge by including as a covariate the fraction of 1991 patients receiving non-medication therapeutic services (denoted NON_MED%).
There is good reason to believe that the development and diffusion of vaccines, as well as drugs, contributes to mortality reduction. The NAMCS file includes data on vaccine utilization; the vaccines cited in the 1991 file are as follows:
Vaccine Unlike a drug, it would not make sense to link a vaccine with the patient' s current diagnosis, since a vaccine is administered to prevent the person from having that diagnosis. Vaccines are therefore excluded from the pharmaceutical variable (DRUGS t-k,t / DRUGS .t ) in equation (1). In order to control (admittedly imperfectly) for the effect of vaccine availability on mortality reduction, we included a dummy variable (denoted VACCINE) equal to one for diseases for which a vaccine was available in 1991, and equal to zero for other diseases.
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The third potential non-pharmaceutical source of mortality reduction we can account for is the rate of introduction of new surgical procedures. Using data from the 1980 and 1991 National
Hospital Discharge Surveys, we construct an index (denoted NEWSURG), by disease, of the rate at which new surgical procedures were introduced during the period 1980-91. 35 Let N ijt represent the number of times surgical procedure i was performed on patients with 2-digit diagnosis j in year t (t=1980, 1991). Then N .jt = Σ i N ijt denotes the total number of surgical procedures performed on patients with diagnosis j in year t, and n ijt = N ijt / N .jt denotes procedure i's share in total procedures performed on patients with diagnosis j in year t. We computed NEWSURG as follows:
This index measures the degree of similarity (or dissimilarity) of disease j's 1980 and 1991 percentage distributions of surgical procedures. 36 It is bounded between zero and one; a value of zero indicates no novelty, i.e. perfect similarity of the two distributions, and a value of one indicates complete novelty, i.e. zero similarity. Table 8 indicates that diseases for which there was a higher probability of physician counseling in 1991 had greater declines in life-years lost between 1970 and 1991; this is consistent with the hypothesis that improved patient knowledge reduces mortality. Column (3) reveals that diseases for which a vaccine was available in 1991 exhibited greater reductions in mortality than non-vaccine diseases. The relationship is not very significant (p-value = .17), however, perhaps due to the crudeness of this measure. When both of these variables and the new drug variable are included in the model (column (4)), the coefficient on the latter is reduced by only 15%, and it remains highly significant. Neither of the other two coefficients is significant at the 5% level. This suggests that failure to account for counseling/education and vaccine availability produces little, if any, upward bias in our estimate of the impact of pharmaceutical innovation on mortality reduction. As might be expected, the coefficient on NEWSURG is positive-consistent with the view that surgical innovation as well as pharmaceutical innovation contributes to mortality reduction-but it is only significant at the 20 percent level. Moreover, both the point estimate of the drug coefficient and its t-statistic are virtually identical to their values when NEWSURG is excluded from the model. 38 Controlling for a potentially important other form of medical innovation has no effect on the estimate of the impact of pharmaceutical innovation.
VI. Estimation of the social rate of return
Our data can be used to obtain approximate measures of the economic benefits (in terms of reduced mortality) of, and social rate of return to, pharmaceutical innovation. Estimates of eq.
(1) provide one possible way to do this. Note that the intercept of this equation, α, is the expected or predicted value of mortality reduction under no innovation, i.e. E[ln (LYL 1970 / LYL 1991 )| (DRUGS 1970 (DRUGS ,1991 / DRUGS .1991 ) = 0] = α. The total benefit of innovation could be measured by the difference between actual mortality reduction and predicted mortality reduction under no innovation. The problem with this approach is that, because there are very few diseases with low values of NEWDRUG%--there is only 1 disease for which NEWDRUG% = 0, and 2 for which NEWDRUG% < 1/3-predicting mortality reduction under no innovation requires extrapolating far from the sample mean and is therefore subject to high forecast error variance.
A second approach, and the one we will adopt because it does not entail extrapolation far from the sample mean, is based on a slightly different functional form of the relationship between the new drug share and mortality reduction. Suppose that there is a log-linear relationship between the ratio of beginning-of-period to end-of-period LYL and the number of drugs approved during the period (APPS):
ln (LYL 1970 / LYL 1991 ) = α + β ln (APPS 1970 (APPS ,1991 )+ ε.
If 0 < β < 1, there are positive but diminishing marginal benefits to approvals. -β is the elasticity of LYL 1991 to APPS 1970 ,1991 , conditional on LYL 1970 : LYL 1991 ) (APPS 1970 (APPS ,1991 ) d ln (APPS 1970 (APPS ,1991 d (APPS 1970 (APPS ,1991 ) (LYL 1991 )
The marginal effect of the number of drugs approved on LYL 1991 is:
effect of NEWSURG is positive and significant and the interaction term is negative and significant. However the marginal effect of surgical novelty, evaluated at the sample mean value of NEWDRUG, is not significantly different from zero (p-value=.49). The significance of the NEWDRUG effect (evaluated at the sample mean value of NEWSURG), increases slightly (the P-value falls from .022 to .004).
d (LYL 1991 ) = -β LYL 1991 d (APPS 1970 (APPS ,1991 APPS 1970, 1991 At the beginning of 1970, 350 drugs had already been approved by the FDA. Hence the percent of drugs approved by the beginning of 1991 that were approved after 1970 (%APP7091) is %APP7091 = APPS 1970 ,1991 / (350 + APPS 1970 ,1991 Solving this expression for APPS 1970 ,1991 , APPS 1970 ,1991 
where α' = α + β ln (350 (and presumably will do so in all future years). This is the "marginal physical product" of new drug approvals. By attaching "prices" to new drug approvals and to life-years, we can calculate the social rate of return to investment in pharmaceutical innovation. Myers and Howe (1997) estimate the cost of a new drug approval to be $697 million with program costs allocated and $429 without program costs. Cutler et al (1996) , citing Viscusi (1993) This should be regarded as a very rough estimate; for a number of reasons it may be either too high or too low. Industry R&D expenditure may understate the true social cost of drug development. Toole (1998) presents evidence consistent with the view that the number of new molecular entities approved in a given year is positively related to government-funded biomedical research expenditure many (e.g. 25) years earlier, as well as to industry-funded R&D. It may therefore be appropriate to include some government-funded R&D in our cost estimate. 40 On the 40 In 1992, about half of total health R&D expenditure in the U.S. was publicly supported, but during the last few decades, private funding has grown much more rapidly than public funding. In 1980, government R&D accounted for almost 80% of U.S. health R&D. Source: National Science Board (1993), p. 365.
other hand, pharmaceutical innovation probably confers benefits other than reduced mortality, such as reduced hospitalization and surgical expenditures (see Lichtenberg (1996) ), reduced workdays and schooldays lost, and improved quality of life; the above calculation does not account for these.
A rate of return of 40% is very high. However, many previous econometric and case studies (see Griliches (1998) ) have indicated that the rate of return to R&D investment in general is high-much higher than the rate of return to ordinary investment. Moreover, Cutler, McClellan, and Newhouse argue that "medical care is a more productive investment than the average use of our funds outside the medical sector," and Nordhaus concluded that "the social productivity of health care spending might be many times that of other spending."
VII. Summary and Conclusions
We have analyzed the relationship across diseases between the long-term reduction in lifeyears lost before age 75 and the relative utilization of new pharmaceutical products. This methodology controls for the effects of any general economic and social trends (such as changes in wealth, nutrition, or sanitation) that affect average mortality. The data we analyzed cover all diseases and all (outpatient) drugs, thus allowing us (assuming that our model is correctly specified) to draw general conclusions about the impact of new drugs on longevity, which it is not possible to do from existing studies, which are about specific diseases and/or drugs.
Previous investigators have argued that increased longevity should be considered an important part of economic growth, and the model we estimated is very consistent with the most widely-accepted theory of growth, which implies that the rate of growth of per capita output depends only on the rate of technological progress. The effect of the new drug share on mortality reduction appears to have been much higher in 1970-80 than it was in 1980-91. Also, the magnitude and significance of this effect is larger over the entire 21-year period than it is in either of the two sub-periods, which is consistent with the view that the long-run effects of new drugs on mortality are larger than the short-run effects. The data provide only weak support for the view that new priority drugs reduce mortality more than new standard drugs.
New drugs appear to have reduced mortality among all broad age groups in one of the two periods. In the 1970-80 period, new drugs reduced mortality only in the lowest and middle thirds of the age-distribution of diseases-especially in the former-while in the 1980-91 period, new drugs had a significant positive effect on mortality reduction only in the highest third of the age distribution. Since the drugs introduced in the 1980s tended to be targeted at older patients than the drugs introduced in the 1970s, this "vintage-age interaction" is not surprising.
Pharmaceutical innovation, like most other economic activities, appears to be subject to the law of diminishing marginal productivity: the estimated elasticity of mortality with respect to the number of new drug approvals is about one-half (e.g., a 10% increase in new drug approvals is estimated to reduce mortality by 5%).
In principle, our initial estimates of the effect of pharmaceutical innovation on mortality reduction could be biased due to failure to control for other determinants of mortality reduction.
But further investigation indicated that controlling for counseling/education and vaccine availability has only a small effect on our estimate of the impact of pharmaceutical innovation on mortality reduction. Controlling for the rate of introduction of new surgical procedures had no effect.
We used the data to obtain approximate measures of the economic benefits (in terms of reduced mortality) of, and social rate of return to, pharmaceutical innovation. On average, each new drug approved during the period 1970-91 is estimated to have saved 11,200 life-years in 1991 (and presumably continued to do so in subsequent years). If, as previous researchers have argued, the value of a life-year is about $25,000, and the average cost of a new drug approval is $697 million, then to a first approximation, the social rate of return to pharmaceutical innovation is about 40%. This is a very high rate of return, but previous studies have also found high social returns to innovation, and have suggested that "the social productivity of health care spending might be many times that of other spending." This estimate only accounts for the mortalityreduction benefits of new drugs; it does not account for possible morbidity reduction or quality-oflife enhancement. We plan to assess these in future research. Table 1 Mean Life Expectancy and Statistics of Age Distribution of Deaths, 1970 Deaths, , 1980 Deaths, , and 1991 Deaths, 1970 Deaths, 1980 Deaths, 1991 Life VACCINE: equals one for diseases for which a vaccine was available in 1991, and equals zero for other diseases.
